

<b>HEALTH TECHNOLOGY APPRAISAL: CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY (2<sup>ND</sup> ACD)</b>	
<b>To: NICE</b>	<b>FROM: NHS Quality Improvement Scotland</b>

Reviewer 1

- i) Whether you consider that all the relevant evidence has been taken into account.  
**YES**
  
- ii) Whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate.  
**YES**
  
- iii) Whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.  
**YES**

Reviewer 2

- i) Whether you consider that all the relevant evidence has been taken into account.

**This document does take into consideration representation from Health professionals relating to the concerns about a small group of ESRD patients**

**with refractory hyperparathyroidism with relative or absolute contra-indications to surgical parathyroidectomy. I would agree that all relevant evidence has been taken into account but accept the reservations of the Committee that there is a paucity of RCT evidence to support use of cinacalcet in these specific 'problem' groups.**

- ii) Whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate. **Yes**
- iii) Whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.

**They are a significant improvement on the earlier recommendations and address the needs of a group of patients where treatment options are currently limited or ineffective. The 'check' of a 30% improvement at 3 months will prevent inappropriate and costly prolonged use of the drug.**

Reviewer 3.

- i) Whether you consider that all the relevant evidence has been taken into account.

**Yes**

- ii) Whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence and that the preliminary views on the resource impact and implications for the NHS are appropriate.

**Yes**

- iii) Whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.

**Yes**

7 September 2006